Analysis of the combined effect of rs699 and rs5051 on angiotensinogen expression and hypertension
Open Access
- 26 December 2023
- journal article
- research article
- Published by Wiley in Chronic Diseases and Translational Medicine
- Vol. 10 (2) , 102-117
Abstract
Background: Hypertension (HTN) involves genetic variability in the renin‐angiotensin system and influences antihypertensive response. We previously reported that angiotensinogen (AGT) messenger RNA (mRNA) is endogenously bound by miR‐122‐5p and rs699 A > G decreases reporter mRNA in the microRNA functional‐assay PASSPORT‐seq. The AGT promoter variant rs5051 C > T is in linkage disequilibrium (LD) with rs699 A > G and increases AGT transcription. The independent effect of these variants is understudied due to their LD therefore we aimed to test the hypothesis that increased AGT by rs5051 C > T counterbalances AGT decreased by rs699 A > G, and when these variants occur independently, it translates to HTN‐related phenotypes.Methods: We used in silico, in vitro, in vivo, and retrospective models to test this hypothesis.Results: In silico, rs699 A > G is predicted to increase miR‐122‐5p binding affinity by 3%. Mir‐eCLIP results show rs699 is 40–45 nucleotides from the strongest microRNA‐binding site in the AGT mRNA. Unexpectedly, rs699 A > G increases AGT mRNA in an AGT‐plasmid‐cDNA HepG2 expression model. Genotype‐Tissue Expression (GTEx) and UK Biobank analyses demonstrate liver AGT expression and HTN phenotypes are not different when rs699 A > G occurs independently from rs5051 C > T. However, GTEx and the in vitro experiments suggest rs699 A > G confers cell‐type‐specific effects on AGT mRNA abundance, and suggest paracrine renal renin‐angiotensin‐system perturbations could mediate the rs699 A > G associations with HTN.Conclusions: We found that rs5051 C > T and rs699 A > G significantly associate with systolic blood pressure in Black participants in the UK Biobank, demonstrating a fourfold larger effect than in White participants. Further studies are warranted to determine if altered antihypertensive response in Black individuals might be due to rs5051 C > T or rs699 A > G. Studies like this will help clinicians move beyond the use of race as a surrogate for genotype.Keywords
All Related Versions
Funding Information
- National Center for Research Resources (RR020128)
- National Institute of General Medical Sciences (1R01GM120156‐01A1, K23GM147805, R35GM131812, T32GM008425)
This publication has 65 references indexed in Scilit:
- Difference in blood pressure response to ACE-Inhibitor monotherapy between black and white adults with arterial hypertension: a meta-analysis of 13 clinical trialsBMC Nephrology, 2013
- PRMT5 dimethylates R30 of the p65 subunit to activate NF-κBProceedings of the National Academy of Sciences of the United States of America, 2013
- Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic reviewBMC Medicine, 2013
- The Relationship Between Angiotensinogen Gene Polymorphisms and Essential Hypertension in a Northern Han Chinese PopulationAngiology, 2013
- Genotype–phenotype analysis of angiotensinogen polymorphisms and essential hypertension: the importance of haplotypesJournal Of Hypertension, 2010
- VARNA: Interactive drawing and editing of the RNA secondary structureBioinformatics, 2009
- Association of renin–angiotensin and endothelial nitric oxide synthase gene polymorphisms with blood pressure progression and incident hypertension: prospective cohort studyJournal Of Hypertension, 2008
- Structural and functional insights into human Tudor-SN, a key component linking RNA interference and editingNucleic Acids Research, 2008
- Variation at the M235T locus of the angiotensinogen gene and essential hypertension: a population-based case-control study from Rochester, MinnesotaHuman Genetics, 1995
- Molecular basis of human hypertension: Role of angiotensinogenCell, 1992